June 17, 2022 |
Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission to drive measurable behaviour change.
Evoke Mind+Matter has continued to strengthen its integrated marcomms offering with the expansion of its in-house market research capabilities.
Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission to drive measurable behaviour change.
Angela McMean, Research Director at Evoke Mind+Matter said: “Our team of research experts are specialists in research methodologies and data analytics. We design and deliver bespoke qualitative and quantitativestudies that include patient, healthcare professional and consumer behaviour analysis, social media and sentiment analysis, market understanding, creative concept and message testing, audience segmentation, real world evidence and communications measurement and evaluation.”
The Evoke Mind+Matter insights division sits within the strategy team headed up in the UK by Simon Grist, Strategy & Insights Director.
Simon Grist, UK Strategy & Insights Director at Evoke Mind+Matter said: “We pride ourselves on delivering against our mission to create meaningful experiences that drive meaningful change. The expansion of our research offering reinforces our commitment to delivering evidence-based strategic programmes built on actionable insights and proven behavioural interventions.”
Evoke Mind+Matter launched a year ago with a fresh, fearless vision of what healthcare communications could be. It closed 2021 with £6m of new business, 200 per cent growth in average client revenue, 60 new hires, months of investment in a new proprietary tech platform (Gravity.ai) and a unique new proposition to create meaningful experiences driven by data and emotion to ultimately change behaviour.
This content was provided by Inizio
Latest Content from Inizio
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence
Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the…
Discover how AI, analytics and real-world data are reshaping Medical Affairs.
Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.
Explore Inizio Medical’s key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.
